Trials / Recruiting
RecruitingNCT06699680
Phase 1 Study of PRX019 in Healthy Adult Volunteers
A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo Controlled, First in Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of Single Ascending and Multiple Doses of PRX019 in Healthy Adults
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- Prothena Biosciences Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the safety and tolerability of PRX019 in healthy adult participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PRX019 | Specified dose on specified days |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2024-11-08
- Primary completion
- 2026-01-23
- Completion
- 2026-01-23
- First posted
- 2024-11-21
- Last updated
- 2024-11-21
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06699680. Inclusion in this directory is not an endorsement.